Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Sanofi SA (SNY) Price & Performance

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETFTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Sanofi SA — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

FLRNSNY
Sector
Sector/ThematicHealth
52-Week High
$30.86$52.34
52-Week Low
$30.65$41.33
Market Cap
$104.30B
Enterprise Value
$124.19B
Dividend Yield
5.55%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.

Read more on FLRN

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY